Beatriz MartÃ-n-Antonio

List of Publications by Year
in descending order

63 papers	1,559 citations	394421 19 h-index	330143 37 g-index
64 all docs	64 docs citations	64 times ranked	2778 citing authors

#	Article	IF	Citations
1	CAR T cells targeting options in the fight against multiple myeloma. Panminerva Medica, 2021, 63, 37-45.	0.8	2
2	Editorial: Understanding the Cytokine Release Syndrome: Toward Improving Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 666703.	4.8	1
3	Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy. Cancers, 2021, 13, 2055.	3.7	5
4	IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation. Cancers, 2021, 13, 3534.	3.7	19
5	Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner. Frontiers in Immunology, 2021, 12, 717850.	4.8	10
6	NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness. , 2021, 9, e002866.		21
7	Inflammaging, an Imbalanced Immune Response That Needs to Be Restored for Cancer Prevention and Treatment in the Elderly. Cells, 2021, 10, 2562.	4.1	13
8	Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. Frontiers in Immunology, 2021, 12, 792609.	4.8	3
9	CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome. Blood, 2021, 138, 735-735.	1.4	7
10	First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma. , 2021, 9, e003783.		17
11	Natural Killer Cells in Immunotherapy: Are We Nearly There?. Cancers, 2020, 12, 3139.	3.7	15
12	Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. Haematologica, 2020, 106, 173-184.	3.5	25
13	In vitro potential of human mesenchymal stem cells for corneal epithelial regeneration. Regenerative Medicine, 2020, 15, 1409-1426.	1.7	15
14	Senescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword. International Journal of Molecular Sciences, 2020, 21, 4346.	4.1	32
15	Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 4688-4698.	7.0	30
16	Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial. Frontiers in Immunology, 2020, 11, 482.	4.8	77
17	104â€...BCMA-targeting CAR-T cells expanded in IL-15 have an improved phenotype for therapeutic use compared to those grown in IL-2 or IL-15/IL-7. , 2020, , .		1
18	102â€...Cord-blood derived NK cells, and CAR-T cells, an attractive improved immunotherapy treatment to be considered for hematological malignancies. , 2020, , .		0

#	Article	IF	Citations
19	Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor. , 2019, 7, 259.		10
20	Exploring NKG2D and BCMA-CAR NK-92 for Adoptive Cellular Therapy to Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e24-e25.	0.4	8
21	Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions. Molecular Therapy - Methods and Clinical Development, 2019, 12, 134-144.	4.1	77
22	Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma. Journal of Immunology, 2018, 200, 2581-2591.	0.8	19
23	CAR-T cell therapy, a door is open to find innumerable possibilities of treatments for cancer patients. Turkish Journal of Haematology, 2018, 35, 217-228.	0.5	9
24	Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma. International Journal of Molecular Sciences, 2018, 19, 3613.	4.1	30
25	A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. Blood Advances, 2018, 2, 1719-1737.	5.2	25
26	Deleterious Effect of Steroids on Cytomegalovirus Infection Rate after Allogeneic Stem Cell Transplantation Depends on Pretransplant Cytomegalovirus Serostatus of Donors and Recipients. Biology of Blood and Marrow Transplantation, 2018, 24, 2088-2093.	2.0	11
27	Natural Killer Cells: Angels and Devils for Immunotherapy. International Journal of Molecular Sciences, 2017, 18, 1868.	4.1	59
28	Natural Killer Cells Transfer Antimicrobial and Antitumoral Histone H2AZ to Kill Multiple Myeloma Cells Contributing to Transmissible Cytotoxicity. Blood, 2016, 128, 2115-2115.	1.4	1
29	The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. PLoS ONE, 2015, 10, e0140454.	2.5	11
30	Overexpression of GYS1, MIF, and MYC Is Associated With Adverse Outcome and Poor Response to Azacitidine in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 236-244.	0.4	31
31	Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking. Cell Death and Differentiation, 2015, 22, 96-107.	11.2	17
32	Cell-Cell Communication Between Multiple Myeloma (MM) Cells and Cord Blood Derived NK Cells (CB-NK) Regulates Both Tumor Cell Death and Tumor Cell Survival. Blood, 2015, 126, 1787-1787.	1.4	1
33	A New Multiple Single-Nucleotide Polymorphisms Based Predictive Model for Grades III to IV and Extensive Graft Versus Host Disease after Identical HLA-Allogeneic Stem-Cell. Blood, 2015, 126, 921-921.	1.4	4
34	Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy, 2014, 16, 84-89.	0.7	42
35	Gene and miRNA Expression Profiles of Hematopoietic Progenitor Cells Vary Depending on Their Origin. Biology of Blood and Marrow Transplantation, 2014, 20, 630-639.	2.0	15
36	Bone marrow mesenchymal stem cells from aplastic anemia patients preserve functional and immune properties and do not contribute to the pathogenesis of the disease. Experimental Hematology, 2014, 42, S50.	0.4	0

#	Article	IF	Citations
37	Granulocyte colony-stimulating factor produces long-term changes in gene and microRNA expression profiles in CD34+ cells from healthy donors. Haematologica, 2014, 99, 243-251.	3.5	13
38	Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease. Haematologica, 2014, 99, 1168-1175.	3.5	36
39	Donor and Recipient Genotypes for Interleukin 1 Gene Single Nucleotide Polymorphisms (SNPs) Allow Anticipation of Acute Graft Versus Host Disease after HLA-Identical Allogeneic Stem Cell Transplantation (allo-SCT). Blood, 2014, 124, 666-666.	1.4	1
40	A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT. Bone Marrow Transplantation, 2013, 48, 1205-1211.	2.4	7
41	Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib. Leukemia Research, 2013, 37, 641-646.	0.8	17
42	Self-Renewing Human Bone Marrow Mesenspheres Promote Hematopoietic Stem Cell Expansion. Cell Reports, 2013, 3, 1714-1724.	6.4	128
43	Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. PLoS ONE, 2013, 8, e76781.	2.5	155
44	Donor Genotypes For Interleukin-17A Gene Single Nucleotide Polymorphisms (SNPs) Allow Anticipation Of Complications After HLA-Identical Allogeneic Stem Cell Transplantation (allo-SCT). Blood, 2013, 122, 4619-4619.	1.4	0
45	NK Cells Kill Myeloma Cells By Increasing ER Stress and Decreasing Autophagy Levels. NKG2D and NKP30 Are Involved In These Processes. Blood, 2013, 122, 3487-3487.	1.4	0
46	A constitutional variant in the transcription factor EP300 strongly influences the clinical outcome of patients submitted to allo-SCT. Bone Marrow Transplantation, 2012, 47, 1206-1211.	2.4	7
47	Mirnas and Gene Expression Profiles in CD34+ Cells Are Dependent On the Source of Progenitor Cells Employed in Transplantation.. Blood, 2012, 120, 3020-3020.	1.4	0
48	A Gene Variant in IRF3 Impacts On the Clinical Outcome of Acute Myeloid Leukemia (AML) Patients Submitted to Allogeneic Stem Cell Transplantation (allo-SCT). Blood, 2012, 120, 468-468.	1.4	4
49	The G-CSF Produces Long-Term Changes in Gene and Mirnas Expression Profiles in CD34+ From Healthy Donors. Blood, 2012, 120, 588-588.	1.4	0
50	Impact of constitutional polymorphisms in VCAM1 and CD44 on CD34+ cell collection yield after administration of granulocyte colony-stimulating factor to healthy donors. Haematologica, 2011, 96, 102-109.	3.5	36
51	Impact of Global and Gene-Specific DNA Methylation Pattern in Relapsed Multiple Myeloma Patients Treated with Bortezomib. Blood, 2011, 118, 132-132.	1.4	0
52	The Genotype in the Donor and Recipient for the Polymorphim â^'174 G/C of the IL-6 Influences the Outcome of HLA-Identical Related Stem Cell Transplantation,. Blood, 2011, 118, 4082-4082.	1.4	0
53	A Recessive Gene Variant in TGFB1 in the Donor Influences the Acute Graft Versus Host Disease Development and Impacts in the Outcome After Allogeneic Stem Cell Transplantation (Allo-SCT),. Blood, 2011, 118, 4080-4080.	1.4	0
54	-52G/A Gene Variant in the Î²-Defensin-1 (DEBF1) Influences the Development of Severe Acute Graft Versus Host Disease (aGvHD) After Allogeneic Stem Cell Transplantation (Allo-SCT). Functional Association of This Variant with a Low Anti- Inflammatory Response. Blood, 2011, 118, 3052-3052.	1.4	0

#	Article	IF	Citations
55	G to C Transition At Position â^'173 of MIF Gene Associates with Poor Survival in Acute Myeloid Leukemia Patients and After Allogeneic Stem Cell Transplantation (Allo-SCT). Blood, 2011, 118, 2530-2530.	1.4	9
56	Genomic polymorphisms of the innate immune system and allogeneic stem cell transplantation. Expert Review of Hematology, 2010, 3, 411-427.	2.2	11
57	Effects of stocking density and feed ration on growth and gene expression in the Senegalese sole (Solea senegalensis): Potential effects on the immune response. Fish and Shellfish Immunology, 2010, 28, 296-302.	3.6	158
58	Cellular and molecular immune responses of the sea bass (Dicentrarchus labrax) experimentally infected with betanodavirus. Fish and Shellfish Immunology, 2010, 28, 303-311.	3.6	77
59	Genetic Variability In the Transcriptional Factor EP300 Strongly Influences the Clinical Outcome of Allogeneic Stem Cell Transplantation (Allo-SCT). Blood, 2010, 116, 527-527.	1.4	0
60	Differential Gene Expression Involved In Angiogenesis, Metabolism, Cell Proliferation and Self-Renewal and Pluripotency In Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 2010, 116, 4646-4646.	1.4	2
61	Genomic characterization and gene expression analysis of four hepcidin genes in the redbanded seabream (Pagrus auriga). Fish and Shellfish Immunology, 2009, 26, 483-491.	3.6	57
62	Molecular characterization, phylogeny, and expression of c-type and g-type lysozymes in brill (Scophthalmus rhombus). Fish and Shellfish Immunology, 2008, 25, 57-65.	3.6	109
63	Intestinal microbiota variation in Senegalese sole (Solea senegalensis) under different feeding regimes. Aquaculture Research, 2007, 38, 1213-1222.	1.8	65